Reply to: Challenging the paradigm
- PMID: 35284016
- PMCID: PMC8908864
- DOI: 10.1183/20734735.0174-2021
Reply to: Challenging the paradigm
Abstract
Inhaled corticosteroids should be targeted to those with documented airway eosinophilia, not prescribed indiscriminately to all who wheeze. Blind steroid treatment without regard to underlying pathophysiology is not 21st century standard of care. https://bit.ly/34lyaJG.
Copyright ©ERS 2022.
Conflict of interest statement
Conflict of interest: A. Bush has nothing to disclose. Conflict of interest: I.D. Pavord reports speaker fees from Aerocrine AB; speaker fees and consultant fees from Almirall and Novartis; speaker fees, payments for organisation of educational events, consultant fees and international scientific meeting sponsorship from AstraZeneca, GSK, Regeneron Pharmaceuticals, Inc, Sanofi, Teva; speaker fees, consultant fees and international scientific meeting sponsorship from Boehringer Ingelheim; grants, speaker fees, consultant fees and international scientific meeting sponsorship from Chiesi; consultant fees from Circassia, Dey Pharma, Genentech, Knopp Biosciences, Merck, MSD, RespiVert, Schering-Plough; and consultant fees and international scientific meeting sponsorship from Napp Pharmaceuticals, outside the submitted work.
Comment on
-
Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease.Breathe (Sheff). 2021 Sep;17(3):210053. doi: 10.1183/20734735.0053-2021. Breathe (Sheff). 2021. PMID: 35035544 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources